The Newest Addition to Our European Arm

Your trials now supported by on-the-ground Clinical Operations & Regulatory experts.

  • Staffed office founded in 2015
  • We’ve been providing coverage to France for more than a decade
  • Dedicated in-country, native staff ready to assist
  • Complete coverage and support for Phase I-IV studies


France Map



A Highly Attractive Proposition

A Highly Attractive Proposition

Strong R&D environment & government backing lend your program support.

  • Agrément CIR tax credits available for French companies
  • One contract template and budget for all sites established by the coordinatingInvestigator, CNOM (Medical council) advice no more needed to start studies.
  • Third largest trials market in Europe with R&D spend approaching €5 billion

Two Leaders in Orphan Drug Development

Getting your rare disease treatment to market with efficiency & effectiveness.

  • In-country staff who leverage experience with local doctors and healthcare providers
  • Access to well-equipped university and regional hospitals as well as specialty sites
  • Data to support FDA/EMA approvals for orphan treatments, including Androgenic Alopecia


Constantly Improving Timelines

EU Directives & Pharm-Olam staff help get your project up and running in weeks.

  • Approval times continue to improve
  • 60 day decisions
  • Applications and Ethics reviews done simultaneously (Central Ethics committee chosen from National coordinator area)
C’est Magnifique!

C’est Magnifique!

Nothing makes us happier than happy clients!

Pharm-Olam excelled by selecting sites with dedicated, experienced investigators and the appropriate patient population, which was not a small task for a study in an orphan population such as Lupus Nephritis. - Associate Director, Clinical Operations

See why working with Pharm-Olam in France could be the best choice for your next study.

Contact Us